Bookbuilding IPO | ₹[.] Cr | Listing at BSE SME |
Maxwell Life Sciences has withdrawn its Initial Public Offer (IPO) documents filed with the exchange on July 1, 2025.
Maxwell Life Sciences IPO was a Book Build Issue of 0.67 crore equity shares consisting of a fresh issue of upto 0.56 crore equity shares and an offer for sale (OFS) of upto 0.11 crore equity shares.
The equity shares were proposed to be listed on the BSE SME. Corporate Professionals Capital Pvt.Ltd. was the book running lead manager and Bigshare Services Pvt.Ltd. was the registrar of the issue.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 66,99,600 shares (agg. up to ₹[.] Cr) |
| Reserved for Market Maker | 3,36,000 shares (agg. up to ₹[.] Cr) |
| Fresh Issue (Ex Market Maker) | 53,13,600 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 10,50,000 shares of ₹10 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 1,55,55,552 shares |
| Share Holding Post Issue | 2,12,05,152 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Mon, Jun 9, 2025 |
| Offer document withdrawn | Tue, Jul 1, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII Shares Offered | Not less than 15% of the Net Issue |
Incorporated in 2004, Maxwell Life Sciences Ltd manufactures pharmaceutical formulations for tablets, capsules, syrups, ointments, creams, liquid orals, dry syrups, and powders.
Its product portfolio comprises more than 150 formulations, including Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Antacid, Anti-Ulcerants, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics, Anti-Fungal and anti-amoebic products.
The company's manufacturing facility is located at Boisar, Maharashtra, across 1,510 square meters, with the capability to produce 180 crore tablets per year, 60 crore capsules per year, 1.80 crores bottles of syrup per year and 1.80 crores tubes of ointment per year.
Its manufacturing process is approved by the World Health organization (WHO) for Good Manufacturing Practices (GMP) and Good Laboratory process (GLP) certification issued by Food & Drugs Administration, Maharashtra.
The company supplies pharmaceutical formulations to private companies, merchant exporters, and the government contracts. Under contract manufacturing, it produces pharmaceutical formulations for private companies or parties, which then market and distribute the products under their brand names, both in the domestic and international markets.
Additionally, it also supplies medicines to government hospitals, departments, public sector units, the armed forces, and other public entities.
Competitive Strengths
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 78.32 | 60.76 | 56.28 | 38.66 |
| Total Income | 95.67 | 81.86 | 47.12 | 29.18 |
| Profit After Tax | 8.51 | 4.67 | 0.72 | -0.20 |
| NET Worth | 20.14 | 11.63 | 6.96 | 6.24 |
| Reserves and Surplus | 16.25 | 7.74 | 3.07 | 2.35 |
| Total Borrowing | 20.82 | 19.97 | 15.79 | 15.02 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹139.85 (-0.71%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹42.23 (-0.14%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹193.00 (-1.28%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹255.40 (-4.99%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹253.70 (-1.11%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹99.40 (+0.00%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹233.95 (+1.72%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹80.00 (+0.00%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹72.00 (+19.99%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹623.80 (+2.01%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,009.00 (+2.47%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.68 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,374.20 (+0.53%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹160.12 (+2.23%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.90 (+0.13%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Upgradation / Construction of the existing premises | 4.85 |
| 2 | Funding capital expenditure requirements for the purchase of plant & machinery and furniture & fixtures | 11.42 |
| 3 | Funding capital expenditure towards establishment of new office premise with interior works and utilities | |
| 4 | To meet working capital requirements of our Company | 19.50 |
| 5 | Repayment/prepayment, in part or full, of certain of our borrowings | |
| 6 | General Corporate Purposes |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 40.16% |
| ROCE | 59.19% |
| RoNW | 40.16% |
| PAT Margin | 5.70% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 100% |
Lead Manager Reports
Maxwell Life Sciences IPO is a SME IPO of 66,99,600 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Maxwell Life Sciences IPO open and close dates are not available as of now.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Maxwell Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Maxwell Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Maxwell Life Sciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Maxwell Life Sciences IPO dates are not announced. Please check back again after some time.
Maxwell Life Sciences IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Maxwell Life Sciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Maxwell Life Sciences IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Maxwell Life Sciences IPO allotment status.
The Maxwell Life Sciences IPO listing date is not yet announced. The tentative date of listing is .
